CAS No.: | 1415456-99-3 |
---|---|
Formula: | C187h291n45o59 |
EINECS: | Cagrilintide |
Type: | Sterile Peptides |
Appearance: | Powder |
Quality: | Technical |
Samples: |
---|
Customization: |
---|
Suppliers with verified business licenses
Product Information
Product Name: Cagrilintide
CAS No.: 1415456-99-3
Purity: >99.0%
Molecular Formula: C187H291N45O59
Molecular Weight: 4409g/mol
Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18diacid-γ-Glu-OEG-OEG)]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Appearance: White Lyophilized powder
Reconstitution: Required
Storage:After reconstitution store at 2°C - 8°C
Description:
Cagrilintide is under development for the treatment of obesity and type 2 diabetes. The drug candidate is administered as a once-daily and once-weekly subcutaneous formulation. It is a long-acting amylin analogue. Amylin is co-located with insu in secretory granules and co-secreted with insu by pancreatic beta cells in response to food intake.
CagriSema is a combination medication of the G receptor agonist sema and cagrilintide. Cagrilinitide mimics the hormone amylin, which is produced by the pancreas. Together with insu, amylin makes people feel satiated or full after eating a meal.
CagriSema is a once-weekly injection of sema and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising new type 2 diabetes treatment.
Measure |
CagriSema |
Sema |
Cagrilinitide |
Number of participants |
31 |
31 |
30 |
Average decrease in A1C |
2.2% |
1.8% |
0.9% |
Percentage of participants with an A1C ≤ 6.5% |
75% |
48% |
17% |
Average decrease in body weight |
15.6% |
5.1% |
8.1% |
Average increase in time in range |
43% | 43.6% | 14.8% |
Suppliers with verified business licenses